Sirolimus for Kaposi's sarcoma in renal-transplant recipients.

By G. Stallone, A. Schena, B. Infante, S. di Paolo, A. Loverre, G. Maggio, E. Ranieri, L. Gesualdo, F. Schena, G. Grandaliano. New England Journal of Medicine, 2005

976 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/c40ca79f169a9133d01d36cda015d63ce54c9713

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. David M. Sabatini
2. D. Guertin
3. Jean J. Zhao
4. T. Roberts
5. M. Laplante
6. T. Franke
7. R. A. Saxton
8. K. Guan

In Oncology

1. David M. Sabatini
2. D. Guertin

In Surgery

1. David M. Sabatini

Citations in the corpus

• Defining the role of mTOR in cancer. (2007, background): “A remarkable successful example of treating tumors using rapamycin is in Kaposi’s sarcoma (KS), a tumor characterized by high vascularization and increased vegf signaling (Campistol et al., 2004; Stallone et al., 2005).”
• Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer (2009, background): “Indeed, rapamycin significantly inhibits the progression of Kaposi's sarcoma in which the driving oncogenic alteration is presumed to be activated VEGF–VEGFR signallin”
• Malignancy after Transplantation (2005, background): “(82) described a series of 15 kidney transplant patients who developed Kaposi’s sarcoma while on a maintenance regimen of CsA, MMF, and prednisone; replacement of CsA and MMF with SRL led to the disappearance of all Kaposi’s sarcoma lesions within 3 months.”